Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Splenic marginal zone lymphoma.

Ahmet Dogan1, Peter G Isaacson

  • 1Department of Histopathology, University, College London, London, United Kingdom. a.dogan@ucl.ac.uk

Seminars in Diagnostic Pathology
|August 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Deployment of AI-driven automated quality control of whole-slide images in a large tertiary cancer center.

Journal of pathology informatics·2026
Same author

Genomic features do not account for differences in multiple myeloma risk by ancestry.

Blood cancer discovery·2026
Same author

Genetic risk and immune dysregulation of classic Hodgkin lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma: a multicentric study.

medRxiv : the preprint server for health sciences·2026
Same author

The impact of metabolic dysfunction-associated steatotic liver disease on non-invasive fibrosis scores in patients with chronic hepatitis B: a multicenter retrospective study.

BMC gastroenterology·2026
Same author

Frequency and Distribution of Lymphatic Filariasis in Somalia: A Single-Center Experience.

Journal of tropical medicine·2026
Same journal

Update on the molecular pathology of the distinctive giant cell, fibro-osseous and bone forming lesions of the jaws.

Seminars in diagnostic pathology·2026
Same journal

Update on the molecular pathology and classification of odontogenic cysts and tumours.

Seminars in diagnostic pathology·2026
Same journal

MDM2 gene amplification in surgical pathology: biology, diagnostic utility, and clinical relevance in the modern era.

Seminars in diagnostic pathology·2026
Same journal

When three negatives equal a positive: Molecular updates of triple-negative breast carcinomas with favorable prognoses.

Seminars in diagnostic pathology·2026
Same journal

Old school, new insight: Revisiting histomorphology in the modern era of prostate cancer risk stratification.

Seminars in diagnostic pathology·2026
Same journal

Recent advances in genetic predisposition to primary testicular tumors.

Seminars in diagnostic pathology·2026
See all related articles

Splenic marginal zone lymphoma (SMZL) is a rare B-cell cancer. Diagnosis involves spleen examination, immunophenotyping, and genetic analysis, aiding differentiation from other lymphomas.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Splenic marginal zone lymphoma (SMZL) is a rare, indolent B-cell lymphoproliferative disorder.
  • It accounts for about 1% of all lymphomas and presents with significant splenomegaly and circulating atypical lymphocytes.
  • Histological examination reveals characteristic splenic infiltration patterns and biphasic morphology within the white pulp.

Purpose of the Study:

  • To provide a comprehensive overview of Splenic marginal zone lymphoma (SMZL).
  • To detail the diagnostic features, including histology, immunophenotype, and genetic characteristics.
  • To highlight the differential diagnosis of SMZL from other lymphoid neoplasms.

Main Methods:

  • Histopathological analysis of spleen, lymph nodes, and bone marrow.

Related Experiment Videos

  • Immunophenotypic characterization of tumor cells using flow cytometry or immunohistochemistry.
  • Genetic studies, including analysis of immunoglobulin heavy-chain gene variable regions and chromosomal abnormalities.

    • Main Results:

    • SMZL exhibits a mature B-cell phenotype, typically expressing IgM and IgD, while lacking markers like CD5, CD23, and CD10.
    • Characteristic genetic abnormality is 7q31-32 allelic loss.
    • Tumor cells may originate from postfollicular or naive B cells.

    Conclusions:

    • Accurate diagnosis of SMZL relies on integrating histological, immunophenotypic, and genetic findings.
    • Distinguishing SMZL from other lymphoid hyperplasias and lymphomas, such as mantle cell lymphoma and follicular lymphoma, is crucial.
    • Understanding the cellular origin and genetic landscape aids in the classification and potential therapeutic strategies for SMZL.